Sternberg, Cora

Publications

Sort by

Co-Author Network

selected publications

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract. Future oncology (London, England). 2025 Academic Article GET IT
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. JCI insight. 2025 Academic Article GET IT
Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis. Oncology and therapy. 2025 Academic Article GET IT
Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway. Future oncology (London, England). 2025 Review GET IT
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy. Future oncology (London, England). 2025 Academic Article GET IT
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy. Urologic oncology. 2025 Academic Article GET IT
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100. Cancers. 2025 Academic Article GET IT
Times cited: 1
Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer. 2025 GET IT
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution. European urology oncology. 2025 Academic Article GET IT
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. European urology. 2025 Academic Article GET IT
Times cited: 1
Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?. Translational cancer research. 2025 Editorial Article GET IT
The use of artificial intelligence for cancer therapeutic decision-making. NEJM AI. 2025 Academic Article GET IT
Clinical trials corner issue 11(1). Bladder cancer (Amsterdam, Netherlands). 2025 Academic Article GET IT
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Academic Article GET IT
Times cited: 20
Mesonephric Adenocarcinoma in a Young Male Patient. 2025 GET IT
Unusual Presentation of Advanced Urothelial Cancer in a Young Patient. 2025 GET IT
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. European urology. 2025 Academic Article GET IT
Times cited: 4
Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists. Urology practice. 2024 Academic Article GET IT
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis. Cancer medicine. 2024 Academic Article GET IT
Times cited: 3
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study. Clinical genitourinary cancer. 2024 Academic Article GET IT
Times cited: 7
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. Nature. 2024 Academic Article GET IT
Times cited: 23
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. The oncologist. 2024 Academic Article GET IT
Times cited: 7
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Academic Article GET IT
Times cited: 16
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. European urology. 2024 Academic Article GET IT
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Times cited: 13
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. BMC cancer. 2024 Academic Article GET IT
Times cited: 10
Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale. Clinical genitourinary cancer. 2024 Review GET IT
Times cited: 3
Clinical Trials Corner Issue 10(2). Bladder cancer (Amsterdam, Netherlands). 2024 Academic Article GET IT
Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology. European urology focus. 2024 Academic Article GET IT
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future oncology (London, England). 2024 Academic Article GET IT
Times cited: 1
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma. European urology focus. 2024 Academic Article GET IT
Times cited: 2
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. European urology. 2024 Academic Article GET IT
Times cited: 24
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium. European journal of cancer. 2024 Academic Article GET IT
Times cited: 3
Clinical Trials Corner Issue 10(1). Bladder cancer (Amsterdam, Netherlands). 2024 Academic Article GET IT
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. The oncologist. 2024 Academic Article GET IT
Times cited: 3
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Academic Article GET IT
Times cited: 41
Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. 2024 GET IT
Times cited: 1
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Academic Article GET IT
Times cited: 48
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. Cold Spring Harbor molecular case studies. 2024 Academic Article GET IT
Clinical Trials Corner Issue 9(4). Bladder cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. European urology oncology. 2023 Academic Article GET IT
Times cited: 10
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of ²²⁵Ac-J591. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 41
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO open. 2023 Review GET IT
Times cited: 22
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. British journal of cancer. 2023 Academic Article GET IT
Times cited: 4
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. European urology. 2023 Academic Article GET IT
Times cited: 18
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER). BMC cancer. 2023 Academic Article GET IT
Times cited: 7
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?. Future oncology (London, England). 2023 Review GET IT
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. The Prostate. 2023 Academic Article GET IT
Times cited: 9
Clinical Trials Corner Issue 9(2). Bladder cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023 Academic Article GET IT
Times cited: 25
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. European urology. 2023 Academic Article GET IT
Times cited: 43
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 151
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 20
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 10
Clinical Trials Corner Issue 9(1). Bladder cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 153
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell reports. Medicine. 2023 Academic Article GET IT
Times cited: 18
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. The Journal of urology. 2023 Academic Article GET IT
Times cited: 13
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. Cancers. 2023 Academic Article GET IT
Times cited: 13
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer. 2023 Academic Article GET IT
Times cited: 5
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Times cited: 18
Clinical Trials Corner Issue 8(4). Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Times cited: 1
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score. Minerva urology and nephrology. 2022 Academic Article GET IT
Times cited: 6
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. The Prostate. 2022 Academic Article GET IT
Times cited: 10
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 57
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?. Future oncology (London, England). 2022 Academic Article GET IT
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. European journal of cancer. 2022 Review GET IT
Times cited: 26
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. ESMO open. 2022 Academic Article GET IT
Times cited: 5
Clinical Trials Corner Issue 8(2). Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Future oncology (London, England). 2022 Comment GET IT
Times cited: 10
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science (New York, N.Y.). 2022 Academic Article GET IT
Times cited: 165
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European journal of cancer. 2022 Review GET IT
Times cited: 25
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 46
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European journal of cancer. 2022 Academic Article GET IT
Times cited: 29
Clinical Trials Corner Issue 7(4). Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future oncology (London, England). 2022 Comment GET IT
Times cited: 5
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature communications. 2022 Academic Article GET IT
Times cited: 10
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
Times cited: 8
Clinical Trials Corner Issue 8(1). Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 5
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate cancer and prostatic diseases. 2022 Academic Article GET IT
Times cited: 14
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2022 Academic Article GET IT
Times cited: 733
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. British journal of clinical pharmacology. 2022 Academic Article GET IT
Times cited: 4
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
Times cited: 34
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. European journal of cancer. 2022 Academic Article GET IT
Times cited: 10
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Cells. 2021 Academic Article GET IT
Times cited: 6
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature medicine. 2021 Academic Article GET IT
Times cited: 103
Application of Artificial Intelligence to Overcome Clinical Information Overload in Urologic Cancer. BJU international. 2021 Review GET IT
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers. 2021 Academic Article GET IT
Times cited: 6
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. European urology. 2021 Review GET IT
Times cited: 107
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European journal of cancer. 2021 Academic Article GET IT
Times cited: 8
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future oncology (London, England). 2021 Academic Article GET IT
Times cited: 8
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Comment GET IT
Times cited: 17
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate cancer and prostatic diseases. 2021 Academic Article GET IT
Times cited: 5
Clinical Trials Corner Issue 7(3). Bladder cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO open. 2021 Academic Article GET IT
Times cited: 23
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. The oncologist. 2021 Academic Article GET IT
Times cited: 11
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
Times cited: 17
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Japanese journal of clinical oncology. 2021 Academic Article GET IT
Times cited: 4
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2021 Academic Article GET IT
Times cited: 45
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European urology. 2021 Academic Article GET IT
Times cited: 18
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London, England). 2021 Academic Article GET IT
Times cited: 266
Clinical Trials Corner Issue 7(2). Bladder cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO open. 2021 Academic Article GET IT
Times cited: 51
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO open. 2021 Academic Article GET IT
Times cited: 8
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 434
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. The Journal of urology. 2021 Academic Article GET IT
Times cited: 9
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 182
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2021 Academic Article GET IT
Times cited: 41
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer treatment reviews. 2021 Review GET IT
Times cited: 55
Clinical Trials Corner Issue 7(1). Bladder cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 147
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2021 Academic Article GET IT
Times cited: 354
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European urology. 2021 Review GET IT
Times cited: 32
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European urology. 2021 Academic Article GET IT
Times cited: 60
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO open. 2021 Academic Article GET IT
Times cited: 43
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Accelerating precision medicine in metastatic prostate cancer. Nature cancer. 2020 Academic Article GET IT
Times cited: 62
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Translational oncology. 2020 Academic Article GET IT
Times cited: 13
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. European urology focus. 2020 Academic Article GET IT
Times cited: 4
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. European urology. 2020 Academic Article GET IT
Times cited: 17
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 1169
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 50
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European journal of cancer. 2020 Academic Article GET IT
Times cited: 24
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 591
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. Urologic oncology. 2020 Academic Article GET IT
Times cited: 4
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO open. 2020 Academic Article GET IT
Times cited: 18
The global landscape of drug development for kidney cancer. Cancer treatment reviews. 2020 Review GET IT
Times cited: 6
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer treatment reviews. 2020 Review GET IT
Times cited: 41
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 339
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2020 Academic Article GET IT
Times cited: 32
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 179
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. JAMA oncology. 2020 Academic Article GET IT
Times cited: 22
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European urology. 2020 Conference Paper GET IT
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 152
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 16
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 75
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). 2019 GET IT
Times cited: 15
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The New England journal of medicine. 2019 Academic Article GET IT
Times cited: 535
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 32
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. JAMA oncology. 2019 Academic Article GET IT
Times cited: 53
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European urology oncology. 2019 Academic Article GET IT
Times cited: 21
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. European urology oncology. 2019 Academic Article GET IT
Times cited: 50
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European urology. 2019 Academic Article GET IT
Times cited: 14
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 411
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 175
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. Journal for immunotherapy of cancer. 2019 Academic Article GET IT
Times cited: 130
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. The oncologist. 2019 Academic Article GET IT
Times cited: 10
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. European urology. 2019 Academic Article GET IT
Times cited: 117
Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future oncology (London, England). 2019 Review GET IT
Times cited: 20
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 95
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical genitourinary cancer. 2019 Academic Article GET IT
Times cited: 13
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European urology oncology. 2019 Academic Article GET IT
Times cited: 16
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future oncology (London, England). 2019 Academic Article GET IT
Times cited: 21
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. European urology oncology. 2018 Academic Article GET IT
Times cited: 27
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Frontiers in oncology. 2018 Academic Article GET IT
Times cited: 33
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 61
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Enzalutamide in Castration-Resistant Prostate Cancer. The New England journal of medicine. 2018 Letter GET IT
Times cited: 10
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World journal of urology. 2018 Guideline GET IT
Times cited: 16
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. European urology oncology. 2018 Academic Article GET IT
Times cited: 11
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU international. 2018 Academic Article GET IT
Times cited: 66
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 91
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 894
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European urology. 2018 Review GET IT
Times cited: 82
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer treatment reviews. 2018 Review GET IT
Times cited: 39
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 47
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical genitourinary cancer. 2018 Academic Article GET IT
Times cited: 38
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European urology. 2018 Review GET IT
Times cited: 378
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. 2018 GET IT
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European journal of cancer. 2018 Academic Article GET IT
Times cited: 34
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 63
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 55
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 9
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. The Journal of urology. 2017 Academic Article GET IT
Times cited: 10
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 24
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 20
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 348
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet (London, England). 2017 Academic Article GET IT
Times cited: 150
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget. 2017 Academic Article GET IT
Times cited: 30
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Times cited: 6
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. British journal of cancer. 2017 Academic Article GET IT
Times cited: 13
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European urology. 2017 Conference Paper GET IT
Times cited: 307
Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. Urologia. 2017 Review GET IT
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. The oncologist. 2017 Academic Article GET IT
Times cited: 69
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European urology focus. 2017 Academic Article GET IT
Times cited: 15
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European journal of cancer. 2017 Academic Article GET IT
Times cited: 19
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2017 Academic Article GET IT
Times cited: 7
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 30
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 2959
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate cancer and prostatic diseases. 2017 Academic Article GET IT
Times cited: 85
The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. European urology focus. 2017 Review GET IT
Times cited: 16
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. Nature reviews. Urology. 2017 Information Resource GET IT
Times cited: 2
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA oncology. 2017 Academic Article GET IT
Times cited: 37
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 243
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European urology. 2016 Academic Article GET IT
Times cited: 60
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO open. 2016 Review GET IT
Times cited: 86
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 54
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World journal of urology. 2016 Academic Article GET IT
Times cited: 9
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European urology. 2016 Academic Article GET IT
Times cited: 371
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. Critical reviews in oncology/hematology. 2016 Review GET IT
Times cited: 8
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 211
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World journal of urology. 2016 Review GET IT
Times cited: 11
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 89
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 529
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. European urology. 2016 Comment GET IT
Times cited: 2
Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?. European urology. 2016 Editorial Article GET IT
Times cited: 5
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European journal of cancer. 2016 Review GET IT
Times cited: 50
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 85
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 1361
Clinical Trials Corner. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Chemotherapy for Muscle-Invasive Bladder Cancer. Current treatment options in oncology. 2016 Review GET IT
Times cited: 20
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Letter GET IT
Times cited: 11
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. 2015 GET IT
Times cited: 24
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 106
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061. Oncology. 2015 Academic Article GET IT
Times cited: 30
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. The oncologist. 2015 Academic Article GET IT
Times cited: 23
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug design, development and therapy. 2015 Review GET IT
Times cited: 55
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Translational andrology and urology. 2015 Review GET IT
Times cited: 21
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 180
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer. 2015 Academic Article GET IT
Times cited: 34
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 134
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 1221
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Oncology. 2015 Academic Article GET IT
Times cited: 28
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted oncology. 2015 Academic Article GET IT
Times cited: 47
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Current drug targets. 2015 Review GET IT
Times cited: 46
Future directions and targeted therapies in bladder cancer. Hematology/oncology clinics of North America. 2014 Review GET IT
Times cited: 21
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 347
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Annals of surgical oncology. 2014 Academic Article GET IT
Times cited: 78
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. The Journal of urology. 2014 Academic Article GET IT
Times cited: 10
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Letter GET IT
Comparing comparators: a look at control arms in kidney cancer studies over the years. British journal of cancer. 2014 Review GET IT
Times cited: 4
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European journal of cancer. 2014 Academic Article GET IT
Times cited: 102
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). European journal of cancer. 2014 Review GET IT
Times cited: 5
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU international. 2014 Academic Article GET IT
Times cited: 12
Reply to S. Barni et Al and M. Sun et Al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Letter GET IT
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 44
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology. 2014 Academic Article GET IT
Times cited: 14
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 143
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. The Journal of urology. 2014 Academic Article GET IT
Times cited: 52
Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 2293
Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Editorial Article GET IT
Times cited: 14
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 Academic Article GET IT
Times cited: 33
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. European urology. 2014 Information Resource GET IT
Times cited: 108
Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease. Oncology. 2014 Academic Article GET IT
Times cited: 25
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. European journal of cancer. 2014 Conference Paper GET IT
Times cited: 134
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 360
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 10
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 246
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 80
Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. European urology. 2014 Editorial Article GET IT
Times cited: 15
Progress in the treatment of advanced prostate cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 34
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC urology. 2013 Academic Article GET IT
Times cited: 37
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 145
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clinical genitourinary cancer. 2013 Review GET IT
Times cited: 28
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013 Academic Article GET IT
Times cited: 33
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 368
Re: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. The Journal of urology. 2013 Comment GET IT
Times cited: 1
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1212
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer. 2013 Academic Article GET IT
Times cited: 59
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. European urology. 2013 Academic Article GET IT
Times cited: 45
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. European journal of cancer. 2013 Academic Article GET IT
Times cited: 61
Reducing the burden of bone metastases: current concepts and treatment options. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Review GET IT
Times cited: 22
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. European journal of cancer. 2013 Academic Article GET IT
Times cited: 398
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. European urology. 2012 Academic Article GET IT
Times cited: 113
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. Frontiers in oncology. 2012 Academic Article GET IT
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 72
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 221
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England). 2012 Academic Article GET IT
Times cited: 745
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. American journal of clinical oncology. 2012 Academic Article GET IT
Times cited: 7
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 951
Metastatic bladder cancer: anything new?. Current opinion in supportive and palliative care. 2012 Review GET IT
Times cited: 11
Novel hormonal therapy for castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Conference Paper GET IT
Times cited: 9
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU international. 2012 Academic Article GET IT
Times cited: 54
Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 2970
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert opinion on drug safety. 2012 Review GET IT
Times cited: 32
Novel agents and approaches for advanced renal cell carcinoma. The Journal of urology. 2012 Review GET IT
Times cited: 80
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 236
Neoadjuvant chemotherapy for invasive bladder cancer. Current urology reports. 2012 Review GET IT
Times cited: 21
Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU international. 2012 Review GET IT
Times cited: 12
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. European urology. 2012 Academic Article GET IT
Times cited: 28
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. European journal of cancer. 2012 Academic Article GET IT
Times cited: 16
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European journal of cancer. 2012 Academic Article GET IT
Times cited: 39
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute. 2012 Review GET IT
Times cited: 201
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU international. 2012 Academic Article GET IT
Times cited: 26
Novel molecular targets for the therapy of castration-resistant prostate cancer. European urology. 2011 Review GET IT
Times cited: 60
Clinical and pharmacokinetic evaluation of satraplatin. Expert opinion on drug metabolism & toxicology. 2011 Review GET IT
Times cited: 39
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. European urology. 2011 Review GET IT
Times cited: 52
Novel treatments for castration-resistant prostate cancer. European journal of cancer. 2011 Review GET IT
Times cited: 6
Contemporary role of androgen deprivation therapy for prostate cancer. European urology. 2011 Review GET IT
Times cited: 225
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European journal of cancer. 2011 Academic Article GET IT
Times cited: 83
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. European urology. 2011 Information Resource GET IT
Times cited: 97
Sequelae of treatment in long-term survivors of testis cancer. European urology. 2011 Information Resource GET IT
Times cited: 59
Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 3938
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 151
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Information Resource GET IT
Times cited: 309
New therapies for castration-resistant prostate cancer: efficacy and safety. European urology. 2011 Review GET IT
Times cited: 114
Contemporary management of metastatic castration-resistant prostate cancer. Current opinion in urology. 2011 Review GET IT
Times cited: 11
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 Academic Article GET IT
Times cited: 83
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. European urology. 2011 Review GET IT
Times cited: 52
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU international. 2011 Academic Article GET IT
Times cited: 36
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet. Oncology. 2011 Academic Article GET IT
Times cited: 288
Toxicities of targeted therapy and their management in kidney cancer. European urology. 2011 Review GET IT
Times cited: 110
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. European journal of cancer. 2010 Academic Article GET IT
Times cited: 45
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet. Oncology. 2010 Academic Article GET IT
Times cited: 823
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer research. 2010 Academic Article GET IT
Times cited: 22
Novel targeted therapy for advanced renal carcinoma: trials in progress. Current opinion in urology. 2010 Review GET IT
Times cited: 6
Sequential use of targeted agents in the treatment of renal cell carcinoma. Critical reviews in oncology/hematology. 2010 Review GET IT
Times cited: 52
Neoadjuvant systemic therapy for urological malignancies. BJU international. 2010 Review GET IT
Times cited: 22
Is there a role for presurgical therapy for renal cell carcinoma?. Expert review of anticancer therapy. 2010 Review GET IT
Times cited: 3
Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010 Review GET IT
Times cited: 96
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet. Oncology. 2010 Review GET IT
Times cited: 115
Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical reviews in oncology/hematology. 2010 Review GET IT
Times cited: 152
Pazopanib in renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 14
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU international. 2010 Review GET IT
Times cited: 207
Role of targeted therapy in the treatment of advanced prostate cancer. BJU international. 2010 Review GET IT
Times cited: 29
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. European journal of cancer. 2010 Academic Article GET IT
Times cited: 12
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Letter GET IT
Times cited: 9
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 2040
The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. International journal of urology : official journal of the Japanese Urological Association. 2010 Review GET IT
Times cited: 10
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical reviews in oncology/hematology. 2010 Review GET IT
Times cited: 95
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 199
Management of good risk germ-cell tumours. BJU international. 2009 Review GET IT
Times cited: 5
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 305
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Academic Article GET IT
Times cited: 110
Metastatic renal cell carcinoma: recent advances in the targeted therapy era. European urology. 2009 Review GET IT
Times cited: 54
Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs of today (Barcelona, Spain : 1998). 2009 Review GET IT
Times cited: 16
Satraplatin for the therapy of castration-resistant prostate cancer. Future oncology (London, England). 2009 Review GET IT
Times cited: 8
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. European urology. 2009 Review GET IT
Times cited: 139
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Academic Article GET IT
Times cited: 81
Expanding the boundaries of clinical practice: building on experience with targeted therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 4
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 109
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 23
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urologic oncology. 2009 Editorial Article GET IT
Optimizing outcomes at every stage of bladder cancer: do we practice it?. Urologic oncology. 2009 Information Resource GET IT
Times cited: 14
Bladder cancer today. BJU international. 2008 Article GET IT
Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU international. 2008 Review GET IT
Times cited: 16
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. European urology. 2008 Review GET IT
Times cited: 81
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. European urology. 2008 Review GET IT
Times cited: 141
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU international. 2008 Academic Article GET IT
Times cited: 34
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 26
Adapting treatment for prostate cancer according to risk of disease progression. Critical reviews in oncology/hematology. 2008 Review GET IT
Times cited: 1
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Critical reviews in oncology/hematology. 2008 Review GET IT
Times cited: 27
Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nature clinical practice. Urology. 2008 Comment GET IT
Times cited: 2
Differences in depressive thoughts between major depressive disorder, IFN-alpha-induced depression, and depressive disorders among cancer patients. Journal of psychosomatic research. 2008 Academic Article GET IT
Times cited: 17
Urologists and clinical trials. Nature clinical practice. Urology. 2008 Editorial Article GET IT
Times cited: 1
The future of prostate cancer. BJU international. 2008 Academic Article GET IT
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert opinion on investigational drugs. 2008 Review GET IT
Times cited: 93
Novel agents for muscle-invasive and advanced urothelial cancer. BJU international. 2007 Review GET IT
Times cited: 13
The evolving role of chemotherapy in advanced urothelial cancer. Current opinion in supportive and palliative care. 2007 Review GET IT
Times cited: 1
Molecular pathways and the hope of targeting angiogenesis. Nature clinical practice. Urology. 2007 Comment GET IT
Times cited: 1
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU international. 2007 Academic Article GET IT
Times cited: 4
Signal-transduction inhibitors in renal cell carcinoma. BJU international. 2007 Review GET IT
Times cited: 12
Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Seminars in oncology. 2007 Review GET IT
Times cited: 14
Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nature clinical practice. Urology. 2007 Review GET IT
Times cited: 14
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 126
Prostate cancer chemotherapy. Interview by Christine McKillop. European urology. 2007 Article GET IT
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Review GET IT
Times cited: 152
State-of-the-art management of metastatic disease at initial presentation or recurrence. World journal of urology. 2006 Review GET IT
Times cited: 13
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Critical reviews in oncology/hematology. 2006 Review GET IT
Times cited: 36
The medical management of prostate cancer: a multidisciplinary team approach. BJU international. 2006 Review GET IT
Times cited: 37
Muscle invasive and metastatic bladder cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Review GET IT
Times cited: 18
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology. 2006 Review GET IT
Times cited: 21
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?. BJU international. 2006 Academic Article GET IT
Times cited: 8
Current indications for chemotherapy in prostate cancer patients. European urology. 2006 Review GET IT
Times cited: 73
Adjuvant bicalutamide for early prostate cancer: an update. Nature clinical practice. Urology. 2006 Academic Article GET IT
Are nomograms better than currently available stage groupings for bladder cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Editorial Article GET IT
Times cited: 161
Current therapies and advances in the treatment of pancreatic cancer. Critical reviews in oncology/hematology. 2006 Review GET IT
Times cited: 85
Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU international. 2006 Comment GET IT
Times cited: 10
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depression and anxiety. 2006 Academic Article GET IT
Times cited: 49
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. European journal of cancer. 2005 Academic Article GET IT
Times cited: 503
Adjuvant chemotherapy for bladder cancer. Expert review of anticancer therapy. 2005 Review GET IT
Times cited: 4
Management of advanced prostate cancer after first-line chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 84
Satraplatin in the treatment of hormone-refractory prostate cancer. BJU international. 2005 Review GET IT
Times cited: 32
Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?. Critical reviews in oncology/hematology. 2005 Review GET IT
Times cited: 23
What's new in the treatment of metastatic kidney cancer?. BJU international. 2005 Review GET IT
Times cited: 7
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005 Academic Article GET IT
Times cited: 214
New treatments for metastatic kidney cancer. The Canadian journal of urology. 2005 Review GET IT
Times cited: 29
Chemotherapy for local treatment of bladder cancer. Seminars in radiation oncology. 2005 Review GET IT
Times cited: 9
Irinotecan chemotherapy associated with transient dysarthria and aphasia. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Letter GET IT
Times cited: 20
Promises and challenges of oncology and hematology, including geriatric oncology. Critical reviews in oncology/hematology. 2004 Editorial Article GET IT
Times cited: 3
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2004 Review GET IT
Times cited: 13
High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Journal of experimental & clinical cancer research : CR. 2003 Academic Article GET IT
Times cited: 10
Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells. Clinical chemistry. 2003 Academic Article GET IT
Times cited: 37
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical reviews in oncology/hematology. 2003 Review GET IT
Times cited: 44
Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer. 2003 Academic Article GET IT
Times cited: 150
Metastatic renal cell cancer treatments. Drugs of today (Barcelona, Spain : 1998). 2003 Review GET IT
Times cited: 8
What's new in the treatment of advanced prostate cancer?. European journal of cancer. 2003 Review GET IT
Times cited: 28
Localized and locally advanced bladder cancer. Current treatment options in oncology. 2002 Review GET IT
Times cited: 5
High-risk metastatic urothelial cancer: chances for cure?. Current opinion in urology. 2002 Review GET IT
Times cited: 23
Highlights of contemporary issues in the medical management of prostate cancer. Critical reviews in oncology/hematology. 2002 Review GET IT
Times cited: 17
Overview of international collaborative group prostate cancer trials. Critical reviews in oncology/hematology. 2002 Review GET IT
Times cited: 3
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (London, England). 2002 Academic Article GET IT
Times cited: 1605
New drugs and new approaches for the treatment of metastatic urothelial cancer. World journal of urology. 2002 Review GET IT
Times cited: 33
Current perspectives in muscle invasive bladder cancer. European journal of cancer. 2002 Review GET IT
Times cited: 29
Guidelines on bladder cancer. European urology. 2002 Guideline GET IT
Times cited: 379
Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. Urology. 2002 Academic Article GET IT
Times cited: 111
Bladder cancer. Critical reviews in oncology/hematology. 2002 Review GET IT
Times cited: 44
Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Review GET IT
Times cited: 23
The management of bladder cancer in the elderly. Tumori. 2002 Conference Paper GET IT
Times cited: 5
Treatment options in hormone resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Review GET IT
Times cited: 4
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001 Academic Article GET IT
Times cited: 208
Systemic treatment and new developments in advanced prostate cancer. European journal of cancer. 2001 Review GET IT
Times cited: 14
Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 45
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Current opinion in urology. 2001 Review GET IT
Times cited: 12
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 629
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. European urology. 2001 Academic Article GET IT
Times cited: 10
Neo-adjuvant chemotherapy in invasive bladder cancer. World journal of urology. 2001 Review GET IT
Times cited: 16
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 22
The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 91
Chemotherapy and management of bladder tumours. BJU international. 2000 Review GET IT
Times cited: 33
Chemotherapy, management of bladder tumours. BJU international. 2000 Academic Article GET IT
Gemcitabine in bladder cancer. Seminars in oncology. 2000 Review GET IT
Times cited: 72
Does extended lymphadenectomy influence prognosis of gastric carcinoma after curative resection?. Hepato-gastroenterology. 2000 Academic Article GET IT
Times cited: 14
Second-line chemotherapy in advanced bladder cancer. Urologia internationalis. 2000 Review GET IT
Times cited: 5
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. European urology. 1999 Academic Article GET IT
Times cited: 158
Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Academic Article GET IT
Times cited: 49
A critical review of the management of bladder cancer. Critical reviews in oncology/hematology. 1999 Review GET IT
Times cited: 11
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clinical chemistry. 1999 Academic Article GET IT
Times cited: 100
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. European urology. 1999 Academic Article GET IT
Times cited: 115
Hormonal Therapy and Radiation Therapy in the Treatment of Locally Advanced Prostate Cancer. Molecular urology. 1999 Academic Article GET IT
Neoadjuvant Hormonal Therapy and Radical Prostatectomy for Locally Advanced Prostate Cancer. Molecular urology. 1999 Academic Article GET IT
Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate and Incidence of Biochemical Recurrence. Molecular urology. 1999 Academic Article GET IT
Pathologic Handling and Reporting of Prostate Tissue Specimens in Patients Receiving Neoadjuvant Hormonal Therapy: Report of the Pathology Committee. Molecular urology. 1999 Academic Article GET IT
Muscle-invasive transitional cell carcinoma of the bladder: strategies for bladder preservation. Current opinion in urology. 1998 Academic Article GET IT
Times cited: 1
The management of stage I testis cancer. The Urologic clinics of North America. 1998 Review GET IT
Times cited: 54
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. The New England journal of medicine. 1997 Academic Article GET IT
Times cited: 1431
Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 19
Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology. 1997 Academic Article GET IT
Times cited: 44
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Urologic oncology. 1997 Academic Article GET IT
Times cited: 3
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. British journal of cancer. 1996 Academic Article GET IT
Times cited: 50
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Seminars in oncology. 1996 Review GET IT
Times cited: 17
Neo-adjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Acta urologica Belgica. 1996 Academic Article GET IT
Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. The Journal of urology. 1995 Academic Article GET IT
Times cited: 91
Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1995 Academic Article GET IT
Times cited: 11
The treatment of advanced bladder cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1995 Review GET IT
Times cited: 65
Bladder preservation--a prospect for patients with urinary bladder cancer. Acta oncologica (Stockholm, Sweden). 1995 Review GET IT
Times cited: 2
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. Urologic oncology. 1995 Academic Article GET IT
Times cited: 14
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer. 1995 Academic Article GET IT
Times cited: 26
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. British journal of cancer. 1994 Academic Article GET IT
Times cited: 27
The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract. Seminars in oncology. 1994 Review GET IT
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer. 1993 Academic Article GET IT
Times cited: 70
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 1993 Academic Article GET IT
Times cited: 46
Carboplatin and 5-fluorouracil in poor performance status patients with advanced urothelial cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1993 Academic Article GET IT
Times cited: 11
Treatment of brain metastases from bladder cancer. The Journal of urology. 1993 Academic Article GET IT
Times cited: 28
Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. The Urologic clinics of North America. 1993 Review GET IT
Times cited: 24
Adjuvant chemotherapy following radical cystectomy. World journal of urology. 1993 Review GET IT
Times cited: 1
Recombinant tumor necrosis factor for superficial bladder tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 1992 Academic Article GET IT
Times cited: 9
Hormone refractory metastatic prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1992 Editorial Article GET IT
Times cited: 14
Post cystectomy adjuvant chemotherapy: a clinical routine?. Progress in clinical and biological research. 1992 Review GET IT
Times cited: 2
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer. 1991 Academic Article GET IT
Times cited: 88
Transurethral resection of the prostate and metastatic prostate cancer. Cancer. 1991 Academic Article GET IT
Times cited: 16
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 1991 Academic Article GET IT
Times cited: 121
Organ conservation and reconstruction in advanced bladder cancer. Progress in clinical and biological research. 1991 Review GET IT
Times cited: 1
The Studer ileal neo-bladder: anatomical and functional characteristics. Progress in clinical and biological research. 1991 Academic Article GET IT
[Chemotherapy in the treatment of advanced urothelial tumors]. Der Urologe. Ausg. A. 1991 Review GET IT
Times cited: 1
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 14
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation. Progress in clinical and biological research. 1990 Academic Article GET IT
Times cited: 20
Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) for infiltrating bladder cancer: initial results in Italy. Progress in clinical and biological research. 1990 Review GET IT
Times cited: 1
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Academic Article GET IT
Times cited: 606
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. British journal of urology. 1989 Academic Article GET IT
Times cited: 100
Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. European journal of cancer & clinical oncology. 1989 Academic Article GET IT
Times cited: 7
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. The Journal of clinical investigation. 1988 Academic Article GET IT
Times cited: 223
Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia. Behring Institute Mitteilungen. 1988 Academic Article GET IT
Times cited: 2
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. The New England journal of medicine. 1988 Academic Article GET IT
Times cited: 801
Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. American journal of clinical oncology. 1988 Academic Article GET IT
Times cited: 5
Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. American journal of clinical oncology. 1988 Academic Article GET IT
Times cited: 4
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of urology. 1988 Academic Article GET IT
Times cited: 427
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. The Journal of urology. 1988 Academic Article GET IT
Times cited: 176
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. The Journal of urology. 1988 Academic Article GET IT
Times cited: 38
Advances in testicular cancer--role of chemotherapy. Progress in clinical and biological research. 1988 Review GET IT
Times cited: 3
Chemotherapeutic management of invasive bladder carcinoma. European urology. 1988 Academic Article GET IT
Times cited: 1
Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Progress in clinical and biological research. 1988 Academic Article GET IT
Times cited: 3
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. Progress in clinical and biological research. 1988 Academic Article GET IT
Times cited: 1
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy. Progress in clinical and biological research. 1988 Review GET IT
Current status of chemotherapy for urothelial tract tumors. Oncology (Williston Park, N.Y.). 1987 Information Resource GET IT
Times cited: 9
Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. American journal of clinical oncology. 1987 Academic Article GET IT
Times cited: 13
Phase II trial of idarubicin in patients with pancreatic cancer. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 3
Advances in the treatment of urothelial tract tumors. The Urologic clinics of North America. 1987 Information Resource GET IT
Times cited: 13
Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse. Cancer research. 1986 Academic Article GET IT
Times cited: 44
Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer treatment reports. 1986 Academic Article GET IT
Times cited: 16
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer chemotherapy and pharmacology. 1986 Academic Article GET IT
Times cited: 16
Phase I/II trial of intravesical methotrexate for superficial bladder tumors. Cancer chemotherapy and pharmacology. 1986 Academic Article GET IT
Times cited: 1
Phase II trial of 10 deaza-aminopterin in patients with bladder cancer. Investigational new drugs. 1986 Academic Article GET IT
Times cited: 4
Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 34
Chemotherapy of urologic malignancies. Seminars in urology. 1985 Information Resource GET IT
Times cited: 34
Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Anticancer research. 1985 Academic Article GET IT
Times cited: 12
N-methylformamide-induced hypophosphatemia. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 4
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. The Journal of urology. 1985 Academic Article GET IT
Times cited: 536
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. American journal of clinical oncology. 1984 Academic Article GET IT
Times cited: 1
Phase II trial of 1,2-diaminocyclohexane-(4-carboxyphthalato) platinum(II) (DACCP) in colorectal carcinoma. American journal of clinical oncology. 1984 Academic Article GET IT
Times cited: 2
Treatment of immunodeficiency with interleukin-2: initial exploration. Journal of biological response modifiers. 1984 Academic Article GET IT
Times cited: 28
Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma. Cancer treatment reports. 1984 Academic Article GET IT
Times cited: 1
Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. American journal of clinical oncology. 1983 Academic Article GET IT
Times cited: 3
Fine flutterings of the aortic valve as demonstrated by aortic valve echocardiograms. American heart journal. 1978 Academic Article GET IT
Times cited: 16

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

missing activity Co-Investigator 2024 - 2026
Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity. awarded by United States Department of Defense Co-Investigator 2021 - 2025

The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles awarded by National Cancer Institute Co-Principal Investigator 2021 - 2026

Higher burden of extrachromosomal DNA amplifications drives worse clinical outcomes in African American bladder cancer patients awarded by Bladder Cancer Advocacy Network, Inc. Key Personnel 2025 - 2026

more ...

less ...

Background

education and training

B.A., University of Pennsylvania 73
M.D., University of Rome Faculty of Medicine and Surgery (Italy) 1989
M.D., University of Pennsylvania 1977

Contact

full name

Cora Sternberg

primary email

cns9006@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Cora Sternberg Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage